Potentia Therapeutics is a biotechnology company pioneering a breakthrough Antibody-Oligonucleotide Conjugate (AOC) platform specifically engineered to treat diseases of the Peripheral Nervous System (PNS). By combining the precision of immunology with the gene-silencing power of short interference RNA (siRNA), the company aims to deliver best-in-class, disease-modifying therapies for patients with limited options. The company’s lead program focuses on developing a first-in-class AOC therapy designed to restore myelin formation and nerve function in patients with Charcot-Marie-Tooth disease 1A (CMT1A). Beyond its lead program, Potentia Therapeutics is leveraging the versatility of its AOC platform to address a broader pipeline of debilitating conditions, including diabetes-related neuropathies (DPN), chemotherapy-induced peripheral neuropathy (CIPN), and age-related hearing loss.